Sprout Pharmaceuticals Receives FDA Approval of ADDYI™ (Flibanserin 100 MG)
First-ever FDA-approved treatment for women’s most common form of sexual dysfunction Raleigh, N.C. – August 18, 2015 – Sprout Pharmaceuticals, Inc. (Sprout) announced today that the U.S. Food and Drug...
View ArticleValeant Pharmaceuticals To Acquire Sprout Pharmaceuticals
Enters Sexual Health Market with FDA-Approved Addyi™ (flibanserin 100mg) ADDYI Expected to Launch in U.S. in the Fourth Quarter of 2015 Laval, Quebec and Raleigh, NC — August 20, 2015 — Valeant...
View ArticleAddyi Certification Press Release and Distribution Strategy
CERTIFICATION PROGRAM NOW AVAILABLE FOR HEALTHCARE PRESCRIBERS AND PHARMACIES TO PRESCRIBE OR DISPENSE ADDYI™ (FLIBANSERIN 100 MG) Raleigh, N.C. – September 21, 2015 – Sprout Pharmaceuticals, Inc....
View Article
